The role of patient and healthcare professionals in the era of new hemophilia treatments in developed and developing countries

被引：23

作者：

Nossair, Fadi ^{[2
,3
]}

Thornburg, Courtney D. ^{[1
]}

机构：

[1] Univ Calif San Diego, Pediat, 3020 Childrens Way,MC 5035, San Diego, CA 92123 USA

[2] Rady Childrens Hosp San Diego, Hemophilia & Thrombosis Treatment Ctr, San Diego, CA USA

[3] Univ Calif San Diego, San Diego, CA USA

来源：

THERAPEUTIC ADVANCES IN HEMATOLOGY | 2018年 / 9卷 / 08期

关键词：

clotting factor; extended half-life; gene therapy; hemophilia; novel therapies; shared decision making; SHARED DECISION-MAKING; RECOMBINANT FACTOR-VIII; GENE-THERAPY; PROPHYLAXIS; LIFE; PREFERENCES; INHIBITORS; MODEL; COMMUNICATION; EXPERIENCE;

D O I：

10.1177/2040620718784830

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Medical decisions in hemophilia care are primarily related to the type of factor replacement and treatment regimen. With the growing number of treatment options for patients with hemophilia, decision making is more complex and requires careful consideration of benefits, risks, and patient goals. Shared decision making and decision-aid tools facilitate patient and healthcare provider communication. In this review, the overall role of shared decision making in medicine is outlined, with special emphasis on models for practical implementation. Examples of shared decision making in hemophilia are outlined, and application to new therapeutics is discussed through a case-based approach.

引用

页码：239 / 249

页数：11

共 53 条

[1] Developing a two-sided intervention to facilitate shared decision-making in haemophilia: decision boxes for clinicians and patient decision aids for patients [J].

Athale, A. ;

Giguere, A. ;

Barbara, A. ;

Krassova, S. ;

Iorio, A. .

HAEMOPHILIA, 2014, 20 (06) :800-806

[2] Novel therapies and current clinical progress in hemophilia A [J].

Balkaransingh, Pauline ;

Young, Guy .

THERAPEUTIC ADVANCES IN HEMATOLOGY, 2018, 9 (02) :49-61

[3] Shared Decision Making - The Pinnacle of Patient-Centered Care [J].

Barry, Michael J. ;

Edgman-Levitan, Susan .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (09) :780-781

[4] Understanding patient preferences and willingness to pay for hemophilia therapies [J].

Chaugule, Shraddha S. ;

Hay, Joel W. ;

Young, Guy .

Patient Preference and Adherence, 2015, 9 :1623-1630

[5]

Chou C., 2018, NEJM CATALYST

[6] The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO [J].

Collins, P. ;

Chalmers, E. ;

Chowdary, P. ;

Keeling, D. ;

Mathias, M. ;

O'Donnell, J. ;

Pasi, K. J. ;

Rangarajan, S. ;

Thomas, A. .

HAEMOPHILIA, 2016, 22 (04) :487-498

[7] A longitudinal study to identify the influence of quality of chronic care delivery on productive interactions between patients and (teams of) healthcare professionals within disease management programmes [J].

Cramm, Jane Murray ;

Nieboer, Anna Petra .

BMJ OPEN, 2014, 4 (09)

[8] Transition considerations for extended half-life factor products [J].

Croteau, S. E. ;

Neufeld, E. J. .

HAEMOPHILIA, 2015, 21 (03) :285-288

[9] Differences between developed and developing countries in paediatric care in haemophilia [J].

De Kleijn, P. ;

Odent, T. ;

Berntorp, E. ;

Hilliard, P. ;

Pasta, G. ;

Srivastava, A. ;

Iliescu, A. ;

Mohanty, S. .

HAEMOPHILIA, 2012, 18 :94-100

[10] Impact of haemophilia with inhibitors on caregiver burden in the United States [J].

DeKoven, M. ;

Karkare, S. ;

Lee, W. C. ;

Kelley, L. A. ;

Cooper, D. L. ;

Pham, H. ;

Powers, J. ;

Wisniewski, T. .

HAEMOPHILIA, 2014, 20 (06) :822-830

← 1 2 3 4 5 6 →